Aviva’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,674
Closed -$786K 876
2025
Q4
$786K Buy
+11,674
New +$785K ﹤0.01% 672
2025
Q1
Sell
-137,413
Closed -$6.57M 865
2024
Q4
$6.57M Buy
137,413
+38,765
+39% +$1.99M 0.02% 502
2024
Q3
$5.65M Buy
98,648
+62,833
+175% +$3.6M 0.01% 463
2024
Q2
$1.88M Hold
35,815
0.01% 590
2024
Q1
$1.46M Buy
35,815
+20,131
+128% +$755K ﹤0.01% 625
2023
Q4
$580K Buy
15,684
+2,754
+21% +$104K ﹤0.01% 856
2023
Q3
$494K Sell
12,930
-575
-4% -$23.6K ﹤0.01% 879
2023
Q2
$487K Buy
13,505
+2,863
+27% +$97.7K ﹤0.01% 878
2023
Q1
$406K Buy
10,642
+1,616
+18% +$75.8K ﹤0.01% 945
2022
Q4
$514K Sell
9,026
-3,663
-29% -$188K ﹤0.01% 953
2022
Q3
$502K Buy
12,689
+3,016
+31% +$133K ﹤0.01% 952
2022
Q2
$426K Buy
+9,673
New +$418K ﹤0.01% 1023
2021
Q1
Sell
-47,332
Closed -$2.02M 958
2020
Q4
$2.02M Sell
47,332
-38,368
-45% -$1.38M 0.01% 676
2020
Q3
$2.25M Sell
85,700
-2,753
-3% -$76.7K 0.01% 723
2020
Q2
$2.37M Sell
88,453
-114,004
-56% -$2.57M 0.01% 599
2020
Q1
$3.64M Buy
+202,457
New +$3.84M 0.03% 563

Other funds holding HALO

Aviva's HALO Position: Q1 2026 in Review

Aviva sold out of Halozyme (HALO) in Q1 2026, closing a stake of 11,674 shares — an estimated $786K sold.

Aviva first reported a position in HALO in Q1 2020 and held it in 16 quarters. The position peaked at $6.57M in Q4 2024. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Aviva reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
  • Aviva sold 11,674 Halozyme shares in Q1 2026, an estimated $786K.
  • Aviva first reported a position in Halozyme in Q1 2020 and held it in 16 quarters.
  • Aviva's Halozyme position peaked at $6.57M in Q4 2024.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.